A 39-week, open-label extension to CCOX189A2360, a 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel trial of 2 different dose regimens of lumiracoxib (100 mg od and 200 mg od initial dose for two weeks followed by 100 mg od) in patients with primary knee osteoarthritis, using celecoxib (200 mg od) as a comparator
Latest Information Update: 21 Jul 2007
At a glance
- Drugs Lumiracoxib (Primary) ; Celecoxib
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Adverse reactions
- Sponsors Novartis
- 21 Jul 2007 New trial record.